(ALNY) Alnylam Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 40.461m USD | Total Return: -3.1% in 12m
Avg Turnover: 294M
Qual. Beats: 1
Rev. Trend: 94.7%
Qual. Beats: 0
Warnings
P/E ratio 76.3
Altman Z'' 0.90 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Alnylam Pharmaceuticals, Inc. (ALNY) is a commercial-stage biopharmaceutical company focused on the development of therapeutics utilizing ribonucleic acid interference (RNAi). The company maintains a diverse portfolio of approved treatments for conditions including hATTR amyloidosis, hypercholesterolemia, and acute hepatic porphyria. Its clinical pipeline spans Phase 1 through Phase 3 trials, targeting hypertension, Alzheimer’s disease, and metabolic disorders.
The company operates within the biotechnology sector, which is characterized by high research and development (R&D) intensity and a reliance on intellectual property protection for specialized drug platforms. Alnylam utilizes a collaborative business model, partnering with major industry players such as Roche, Novartis, and Sanofi to co-develop and commercialize its RNAi-based candidates.
For a more detailed look at the financial health of this biotech leader, review the latest metrics on ValueRay. Alnylam is headquartered in Cambridge, Massachusetts, and has maintained its focus on RNAi technology since its founding in 2002.
- Expansion of Amvuttra into ATTR cardiomyopathy market drives long-term revenue growth
- Phase 3 data readouts for Zilebesiran determine hypertension market commercial potential
- Royalty income from Novartis for Leqvio influences quarterly net margin performance
- FDA regulatory decisions on pipeline assets impact short-term equity valuation volatility
- Strategic R&D collaborations with Roche and Regeneron provide essential non-dilutive funding
| Net Income: 577.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 10.21 > 1.0 |
| NWC/Revenue: 66.94% < 20% (prev 93.38%; Δ -26.44% < -1%) |
| CFO/TA 0.14 > 3% & CFO 712.9m > Net Income 577.2m |
| Net Debt (-811.7m) to EBITDA (806.9m): -1.01 < 3 |
| Current Ratio: 3.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago 6.59% < -2% |
| Gross Margin: 80.89% > 18% (prev 86.01%; Δ -5.12% > 0.5%) |
| Asset Turnover: 91.76% > 50% (prev 55.72%; Δ 36.04% > 0%) |
| Interest Coverage Ratio: 2.66 > 6 (EBIT TTM 752.1m / Interest Expense TTM 283.3m) |
| A: 0.56 (Total Current Assets 4.22b - Total Current Liabilities 1.35b) / Total Assets 5.13b |
| B: -1.27 (Retained Earnings -6.50b / Total Assets 5.13b) |
| C: 0.16 (EBIT TTM 752.1m / Avg Total Assets 4.67b) |
| D: 0.27 (Book Value of Equity 1.08b / Total Liabilities 4.05b) |
| Altman-Z'' = 0.90 = BB |
| DSRI: 1.16 (Receivables 884.0m/418.0m, Revenue 4.29b/2.35b) |
| GMI: 1.06 (GM 86.01% / 80.89%) |
| AQI: 0.67 (AQ_t 0.04 / AQ_t-1 0.06) |
| SGI: 1.83 (Revenue 4.29b / 2.35b) |
| TATA: -0.03 (NI 577.2m - CFO 712.9m) / TA 5.13b) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of June 12, 2026, the stock is trading at USD 289.39 with a total of 1,049,755 shares traded.
Over the past week, the price has changed by -4.69%,
over one month by +1.60%,
over three months by -9.69% and
over the past year by -3.08%.
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALNY.
- StrongBuy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 445.8 | 54.1% |
P/E Trailing = 76.335
P/E Forward = 32.4675
P/S = 9.4382
P/B = 37.6248
P/EG = 0.5173
Revenue TTM = 4.29b USD
EBIT TTM = 752.1m USD
EBITDA TTM = 806.9m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.7m USD (from shortTermDebt, last quarter)
Debt = 1.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 263.7m
Net Debt = -811.7m USD (calculated: Debt 1.54b - CCE 2.35b)
Enterprise Value = 39.6b USD (40.5b + Debt 1.54b - CCE 2.35b)
Interest Coverage Ratio = 2.66 (Ebit TTM 752.1m / Interest Expense TTM 283.3m)
EV/FCF = 69.09x (Enterprise Value 39.6b / FCF TTM 573.9m)
FCF Yield = 1.45% (FCF TTM 573.9m / Enterprise Value 39.6b)
FCF Margin = 13.39% (FCF TTM 573.9m / Revenue TTM 4.29b)
Net Margin = 13.46% (Net Income TTM 577.2m / Revenue TTM 4.29b)
Gross Margin = 80.89% ((Revenue TTM 4.29b - Cost of Revenue TTM 819.0m) / Revenue TTM)
Gross Margin QoQ = 81.91% (prev 75.60%)
Tobins Q-Ratio = 7.73 (Enterprise Value 39.6b / Total Assets 5.13b)
Interest Expense / Debt = 18.43% (Interest Expense 283.3m / Debt 1.54b)
Taxrate = 1.57% (9.18m / 586.4m)
NOPAT = 740.4m (EBIT 752.1m * (1 - 1.57%))
Current Ratio = 2.86 (Total Current Assets 4.22b / Total Current Liabilities 1.48b)
Debt / Equity = 1.43 (Debt 1.54b / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = -1.01 (Net Debt -811.7m / EBITDA 806.9m)
Debt / FCF = -1.41 (Net Debt -811.7m / FCF TTM 573.9m)
Total Stockholder Equity = 587.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.36% (Net Income 577.2m / Total Assets 5.13b)
RoE = 98.29% (Net Income TTM 577.2m / Total Stockholder Equity 587.3m)
RoCE = 47.11% (EBIT 752.1m / Capital Employed (Equity 587.3m + L.T.Debt 1.01b))
RoIC = 20.50% (NOPAT 740.4m / Invested Capital 3.61b)
WACC = 7.53% (E(40.5b)/V(42.0b) * Re(7.13%) + D(1.54b)/V(42.0b) * Rd(18.43%) * (1-Tc(0.02)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.21 | Cagr: 4.34%
[DCF] Terminal Value 77.97% ; FCFF base≈360.8m ; Y1≈413.5m ; Y5≈608.6m
[DCF] Fair Price = 74.68 (EV 9.16b - Net Debt -811.7m = Equity 9.97b / Shares 133.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.96 | # QB: 1
Revenue Correlation: 94.68 | Revenue CAGR: 43.10% | SUE: 0.42 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.17 | Chg30d=+4.83% | Revisions=-33% | Analysts=14
EPS next Quarter (2026-09-30): EPS=2.46 | Chg30d=+3.79% | Revisions=-60% | Analysts=14
EPS current Year (2026-12-31): EPS=9.51 | Chg30d=+1.88% | Revisions=+6% | GrowthEPS=+87.2% | GrowthRev=+51.1%
EPS next Year (2027-12-31): EPS=13.90 | Chg30d=+0.17% | Revisions=-29% | GrowthEPS=+46.1% | GrowthRev=+30.1%
[Analyst] Revisions Ratio: -60%